---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-22-000057"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2022-09-06T23:59:59+00:00"
generated_at: "2026-06-23T15:36:18.961237+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Arcutis appoints Neha Krishnamohan to Board of Directors and audit committee

## Summary
- Board expanded from 9 to 10; Krishnamohan appointed Class III director and audit committee member.
- Krishnamohan is CFO and EVP of Corporate Development at Kinnate Biopharma; previously VP at Goldman Sachs.
- Received stock option for 29,482 shares vesting over three years; eligible for $40,000 annual retainer plus $10,000 for audit committee.
- Krishnamohan worked on Arcutis' 2020 IPO while at Goldman Sachs.
- Appointment effective September 2, 2022.

## SEC filing metadata
- accession: 0001787306-22-000057
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2022-09-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000057/0001787306-22-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000057/arqt-20220902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-22-000057
- JSON: https://secwatch.observer/filing/0001787306-22-000057.json
- Plain text: https://secwatch.observer/filing/0001787306-22-000057.txt

## Key facts
- Executive change
  Neha Krishnamohan was appointed as Class III Director and Audit Committee Member at Arcutis Biotherapeutics, Inc..
  - Action: appointed
  - Role: Class III Director and Audit Committee Member
  source text: Effective as of September 2, 2022, the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) directors to ten (10) directors and appointed Neha Krishnamohan to the Board as a new Class III director and as a member of the Audit Committee of the Board (the “Audit Committee”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000057/0001787306-22-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.